Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 7:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hemoglobinopathy (Disorder) Clear all
Completed No phase listed Observational

A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease

NCT02261480
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Blood draw, Nasopharyngeal wash
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced Jun 10, 2026, 7:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

NCT03128996
View directory record Official record
Conditions
Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders
Interventions
RIC regimen, GVHD prophylaxis regimen
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Day to 21 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2033
U.S. locations
4
States / cities
New Haven, Connecticut • Wilmington, Delaware • Grand Rapids, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jun 10, 2026, 7:09 PM EDT
Enrolling by invitation No phase listed Observational

Decision-Making and Quality of Life Surrounding Hematologic Disease and Gene Therapy

NCT06664541
View directory record Official record
Conditions
Transfusion Dependent Beta Thalassemia, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Jun 10, 2026, 7:09 PM EDT
Recruiting Phase 1 Interventional

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

NCT07187973
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
DISC-3405
Drug
Lead sponsor
Disc Medicine, Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 10, 2026, 7:09 PM EDT
Not listed Phase 2 Interventional

Rifaximin to Modify the Disease Course in Sickle Cell Disease

NCT03719729
View directory record Official record
Conditions
Sickle Cell Disease, Antibiotics
Interventions
Rifaximin
Drug
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Jun 10, 2026, 7:09 PM EDT
Completed Phase 2 Interventional Results available

Evaluating the Safety and Effectiveness of Decitabine in People With Thalassemia Intermedia

NCT00661726
View directory record Official record
Conditions
Thalassemia
Interventions
Decitabine (USAN, INN)
Drug
Lead sponsor
Carelon Research
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Oakland, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Jun 10, 2026, 7:09 PM EDT
Recruiting Phase 1Phase 2 Interventional

ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia

NCT06364774
View directory record Official record
Conditions
Beta-Thalassemia
Interventions
ALS20
Biological
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jun 10, 2026, 7:09 PM EDT
Completed Phase 1Phase 2 Interventional

Intravenous Gammaglobulin for Sickle Cell Pain Crises

NCT01757418
View directory record Official record
Conditions
Sickle Cell Disease, Pain
Interventions
Immune Globulin Intravenous (IVIG), Normal saline
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
6 Years to 13 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Jun 10, 2026, 7:09 PM EDT
Completed No phase listed Observational Results available

Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease

NCT02410811
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cardiac magnetic resonance imaging (CMR)
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Jun 10, 2026, 7:09 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Omega-3 Fatty Acids in Sickle Cell Disease

NCT02947100
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SCD-Omegatex™
Drug
Lead sponsor
Robin E. Miller
Other
Eligibility
8 Years to 25 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Jun 10, 2026, 7:09 PM EDT
Terminated Not applicable Interventional Results available

Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO

NCT00578292
View directory record Official record
Conditions
Thalassemia
Interventions
Busulfan, Fludarabine, Campath 1H, Cyclophosphamide, MESNA
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Jun 10, 2026, 7:09 PM EDT
Recruiting Phase 2 Interventional

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

NCT03121001
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
ATG, fludarabine, cyclophosphamide, Total body irradiation, Stem cell infusion, Sirolimus, mycophenolate mofetil
Drug · Radiation · Procedure
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
16 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jun 10, 2026, 7:09 PM EDT
Completed No phase listed Observational

Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease

NCT02227472
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Evaluation of cognitive and pre-academic skills, Parent questionnaires
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
48 Months to 68 Months
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Jun 10, 2026, 7:09 PM EDT
Recruiting No phase listed Observational

A Long-term Follow-up Study in Patients Who Received BEAM-101

NCT07373639
View directory record Official record
Conditions
Hemoglobinopathy, Sickle Cell Disease
Interventions
Long-Term Follow-up Study of patients who received BEAM-101
Drug
Lead sponsor
Beam Therapeutics Inc.
Industry
Eligibility
14 Years to 37 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2043
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jun 10, 2026, 7:09 PM EDT
Completed Phase 2 Interventional Results available

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

NCT02757885
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Bone Marrow Transplant (BMT), Hydroxyurea, Thiotepa, Fludarabine monophosphate, Cyclophosphamide, Rabbit Anti-thymocyte Globulin, Total Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Emory University
Other
Eligibility
15 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Jun 10, 2026, 7:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects

NCT02497924
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Jun 10, 2026, 7:09 PM EDT
Completed Phase 1 Interventional

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease

NCT01522547
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
pomalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Jun 10, 2026, 7:09 PM EDT
Completed Phase 2 Interventional

Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis

NCT01119833
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Pain Crisis
Interventions
GMI-1070, Placebo
Drug
Lead sponsor
GlycoMimetics Incorporated
Industry
Eligibility
12 Years to 60 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
21
States / cities
Birmingham, Alabama • Berkeley, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Jun 10, 2026, 7:09 PM EDT
Completed Not applicable Interventional

Adherence to Hydroxyurea in Children With Sickle Cell Anemia

NCT00672789
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Blood smear education, standard education
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
2 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Jun 10, 2026, 7:09 PM EDT
Terminated Not applicable Interventional Results available

Bi-Level Positive Airway Ventilation for Acute Chest Syndrome

NCT01589926
View directory record Official record
Conditions
Sickle Cell Anemia, Acute Chest Syndrome
Interventions
Bi-level positive airway pressure device, Sham CPAP
Device
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
4 Years to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Jun 10, 2026, 7:09 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Metabolic and Hemodynamic Reserve in Pediatric SCA

NCT04406818
View directory record Official record
Conditions
Child, Only, Brain Diseases, Sickle Cell Disease, Anemia, Sickle Cell
Interventions
Carbon Dioxide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
4 Years to 21 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jun 10, 2026, 7:09 PM EDT
Completed Phase 1Phase 2 Interventional

Reduced Intensity Transplant Using Extracorporeal Photopheresis

NCT00179790
View directory record Official record
Conditions
Leukemia, Cancer
Interventions
Extracorporeal Photopheresis
Procedure
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Jun 10, 2026, 7:09 PM EDT
Completed No phase listed Observational

Improving Emergency Department Management of Adults With Sickle Cell Disease

NCT01603160
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Quality Improvement
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Jun 10, 2026, 7:09 PM EDT
Recruiting Not applicable Interventional

Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease

NCT07402811
View directory record Official record
Conditions
Chronic Pain, Sickle Cell Disease, Sleep Disturbance
Interventions
Mobile bindfulness-based intervention
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
15 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 10, 2026, 7:09 PM EDT